1-(4-Chlorophenyl)-3-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]urea | 138354-52-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 1-(4-Chlorophenyl)-3-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]urea
• CAS: 138354-52-6
• 化学式: C₂₄H₂₁ClN₂O
• 分子量: 388.897
• InChiKey: CMBCGBMKIYHKDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  10,11-二氢二苯并[a,b]环庚烯-5-酮 在 lithium aluminium tetrahydride 、 三氯化铝 、 sodium hydride 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 76.33h， 生成 1-(4-Chlorophenyl)-3-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]urea
  参考文献：
  名称：

  Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718

  摘要：

  A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized. Designed on the basis of the structural homology between lorglumide and L-364,718, as investigated with molecular modeling, these compounds constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists. The prepared compounds were tested in vitro as antagonists of the binding of [H-3]-(+/-)-L-364,718 and [H-3]-CCK-8(S) to rat pancreas and guinea pig brain membranes, respectively. All compounds proved to be selective for the (peripheral) CCK-A receptor, the most potent analogue, 6, having a K(i) value of 90 nM. The structure-activity profile of the series of hybrid compounds relates closest to that of the N-acylglutamic acid derived antagonists.

  DOI：

  10.1021/jm00084a009

文献信息

• Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718
  作者：Arie Van der Bent、Armand G. S. Blommaert、Caroline T. M. Melman、Adriaan P. IJzerman、Ineke Van Wijngaarden、Willem Soudijn

  DOI：10.1021/jm00084a009

  日期：1992.3

  A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized. Designed on the basis of the structural homology between lorglumide and L-364,718, as investigated with molecular modeling, these compounds constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists. The prepared compounds were tested in vitro as antagonists of the binding of [H-3]-(+/-)-L-364,718 and [H-3]-CCK-8(S) to rat pancreas and guinea pig brain membranes, respectively. All compounds proved to be selective for the (peripheral) CCK-A receptor, the most potent analogue, 6, having a K(i) value of 90 nM. The structure-activity profile of the series of hybrid compounds relates closest to that of the N-acylglutamic acid derived antagonists.